Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States

Methodist Health System

Status: Completed

Conditions: Hypercoagulable States

Treatments: Other: Observational

Study type: Observational

Funder types: Other

Identifiers

NCT04565977

042.PHA.2020.A

Details and patient eligibility

About

Retrospective, cohort study chart review in patients with hypercoagulable states.

Full description

• Retrospective, cohort study chart review in patients at Methodist Health System
• Data will be pulled on all patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019

Enrollment: 42 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients ≥ 18 year-old
• Patients with diagnosis of hypercoagulable state identified by ICD-9/ICD-10 codes
• Patients who were prescribed DOACs or VKA for primary or secondary prevention of thrombosis

Exclusion criteria

• Patients with FDA-approved indications of oral anticoagulants including atrial fibrillation or treatment/prevention of thrombotic events unrelated to specified hypercoagulable states
• Patients with incomplete electronic medical records

Trial design

42 participants in 1 patient group

Retrospective Cohort

Description:

All patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019

Treatment:

Other: Observational